TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18380893

Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (ddAT) chemotherapy with tamoxifen
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (ddAT) chemotherapy without tamoxifen
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 248
Study: 16644314

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 1993

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 1993

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 1993
Study: 14768513

Group type: EXPERIMENTAL
Intervention: Isoflurane-based anesthesia
Number of subjects: 107
Study: 10713563

Group type: EXPERIMENTAL
Intervention: PEO/PBT 70/30 (degradable implants)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (untreated defect)
Number of subjects: 7
Study: 9121826

Group type: EXPERIMENTAL
Intervention: Cold pressor task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forearm ischemia task
Number of subjects: 0
Study: 2003657

Group type: EXPERIMENTAL
Intervention: 100 mg labetalol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 200 mg labetalol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg labetalol
Number of subjects: 36
Study: 6361759

Group type: EXPERIMENTAL
Intervention: Chronic 4L plasma exchange therapy with albumin replacement
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Chronic 4L plasma exchange therapy with plasma replacement
Number of subjects: 39

Group type: COMPARATOR
Intervention: Chronic 4L plasma exchange therapy
Number of subjects: 39
Study: 30362445

Group type: EXPERIMENTAL
Intervention: Expressive suppression (ES)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 29700412

Group type: EXPERIMENTAL
Intervention: Feeding infants with their head in upright position
Number of subjects: 163

Group type: COMPARATOR
Intervention: Feeding infants without special instructions (control group)
Number of subjects: 163
Study: 26662838

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml (Gla‐300)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/ml (Gla‐100)
Number of subjects: 241
Study: 24956862

Group type: EXPERIMENTAL
Intervention: Detoxifying and blood circulation activating treatment with extraction of polygonum cuspidatum and hawthorn, 1 pill po, bid (5.33 mg x kg(‐1) x d(‐1) polygonum cuspidatum extraction, 5.0 mg x kg(‐1) x d(‐1) hawthorn extraction)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lovastatin 20 mg po, qd (0.33 mg x kg(‐1) x d(‐1))
Number of subjects: 64
Study: 22326943

Group type: EXPERIMENTAL
Intervention: Caffeine (50 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: L-theanine (100 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of caffeine and L-theanine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20594555

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 17030353

Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy
Number of subjects: 218
Study: 15944559

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (20 to 50 units)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 30
Study: 12092010

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens for gestational trophoblastic neoplasia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective randomized studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carefully planned prospective studies
Number of subjects: 0
Study: 10342081

Group type: EXPERIMENTAL
Intervention: Moistened misoprostol
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dry misoprostol
Number of subjects: 240
Study: 9110389

Group type: EXPERIMENTAL
Intervention: Psychological General Well‐being (PGWB) index
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Gastrointestinal Symptom Rating Scale (GSRS)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Reference group (healthy controls)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: GORD patients
Number of subjects: 900
Study: 1764652

Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialist (CNS) interactions and care before and after hospital discharge
Number of subjects: 36
Study: 6630968

Group type: EXPERIMENTAL
Intervention: Gastric CEA measurement in patients with gastric ulcer and gastric cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastric CEA measurement
Number of subjects: 0
Study: 30917017

Group type: EXPERIMENTAL
Intervention: Voluntary medical male circumcision (VMMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (uncircumcised men)
Number of subjects: 0
Study: 28560658

Group type: EXPERIMENTAL
Intervention: Pradefovir 10 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pradefovir 90 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pradefovir 120 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25203281

Group type: EXPERIMENTAL
Intervention: Blocking inter-trial interval across different blocks of trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varying inter-trial interval from trial to trial
Number of subjects: 0
Study: 26121880

Group type: EXPERIMENTAL
Intervention: Nobecutan® aerosol
Number of subjects: 0
Study: 23026845

Group type: EXPERIMENTAL
Intervention: Ziprasidone with lithium or valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with lithium or valproate
Number of subjects: 0
Study: 19744533

Group type: EXPERIMENTAL
Intervention: Exposure to pictures of fruits and vegetables (reading a picture book daily for two weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No exposure (neophobic behavior towards unexposed foods)
Number of subjects: 20
Study: 17550998

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone supplementation (100 mg im every 2 weeks for 26 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15047641

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg titrated to 100 mg)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 11401641

Group type: COMPARATOR
Intervention: timolol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: latanoprost (50 microg/ml once daily)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: latanoprost in addition to timolol
Number of subjects: 53
Study: 9400510

Group type: EXPERIMENTAL
Intervention: Brief non-directive psychotherapy (1 to 12 sessions over 12 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine general-practitioner care
Number of subjects: 136
Study: 8217970

Group type: EXPERIMENTAL
Intervention: Sweeping the membranes
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (no sweeping)
Number of subjects: 195
Study: 3736870

Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physostigmine
Number of subjects: 0
Study: 30676213

Group type: EXPERIMENTAL
Intervention: Pole walking program (12 weeks)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study: 29282768

Group type: EXPERIMENTAL
Intervention: Paracetamol (3 g/day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (max. 10 μg/h/7 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo transdermal patches
Number of subjects: 106
Study: 27572001

Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT) for 24 months
Number of subjects: 1970

Group type: COMPARATOR
Intervention: Short dual antiplatelet therapy (DAPT) for ≤6 months
Number of subjects: 1970
Study: 24515307

Group type: EXPERIMENTAL
Intervention: Risk score for contrast-induced nephropathy (CIN)
Number of subjects: 3945
Study: 23398269

Group type: EXPERIMENTAL
Intervention: Multicondition collaborative care intervention for chronic illnesses and depression
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 214
Study: 20940640

Group type: EXPERIMENTAL
Intervention: Elastic bands during squats
Number of subjects: 20

Group type: COMPARATOR
Intervention: No elastic bands during squats
Number of subjects: 20
Study: 18375893

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel 80 mg/m2
Number of subjects: 735

Group type: COMPARATOR
Intervention: Every-3-weeks paclitaxel 175 mg/m2
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Trastuzumab in HER-2 nonoverexpressors
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 735

Group type: COMPARATOR
Intervention: Every-3-weeks paclitaxel
Number of subjects: 735
Study: 16361020

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Standard low‐intensity intervention
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Standard high‐intensity intervention
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Standard swallowing therapy
Number of subjects: 306
Study: 12873289

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Soluble human insulin (HI)
Number of subjects: 424
Study: 11077352

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.2% solution (CIP)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Combination of polymyxin B, neomycin, and hydrocortisone suspension (PNH)
Number of subjects: 232
Study: 8808861

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg as needed, 12 to 24 hours before sexual activity)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg as needed)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1442579

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily
Number of subjects: 291

Group type: COMPARATOR
Intervention: Pravastatin 10 mg once daily
Number of subjects: 291
Study: 7031208

Group type: EXPERIMENTAL
Intervention: Twice daily injections of mixed insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-dose insulin regimen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hospital evaluation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standardized exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C-Peptide concentrations
Number of subjects: 10
Study: 30795775

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing Bifidobacterium longum BB536 and red yeast rice extract (10 mg/day monacolin K)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 29106031

Group type: EXPERIMENTAL
Intervention: Morning administration of valsartan/amlodipine (80/5 mg)
Number of subjects: 23
Study: 25448024

Group type: EXPERIMENTAL
Intervention: Medial laminectomy (n=34)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lateral laminectomy (n=38)
Number of subjects: 72
Study: 23414938

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 21989290

Group type: EXPERIMENTAL
Intervention: Booster vaccination with three doses of HepB (CHO) vaccine (20μg each) administered at zero, one, and six months.
Number of subjects: 448

Group type: COMPARATOR
Intervention: Group I (anti-HBs < 0.1 mIU/mL)
Number of subjects: 448
Study: 19329404

Group type: EXPERIMENTAL
Intervention: Modest lifestyle intervention
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Combined intervention group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Follow-up support
Number of subjects: 79
Study: 17326736

Group type: EXPERIMENTAL
Intervention: Mapleson C circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laerdal circuit
Number of subjects: 20
Study: 16792344

Group type: EXPERIMENTAL
Intervention: 24% edetic acid in sterile distilled water applied to the root surface for 2 minutes before grafting
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sterile distilled water (control)
Number of subjects: 10
Study: 14737878

Group type: EXPERIMENTAL
Intervention: Capsaicin (5 mg/mL, 30 microL applied topically)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 16
Study: 10493207

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 7485814

Group type: EXPERIMENTAL
Intervention: Urge generation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Drug (Placebo) Consumption
Number of subjects: 84

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 84
Study: 1791769

Group type: EXPERIMENTAL
Intervention: Once-weekly (17 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Twice-weekly (34 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Two years of twice-weekly treatment (9 women)
Number of subjects: 51
Study: 7199806

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Not using oral contraceptives (Control)
Number of subjects: 812
Study: 30043065

Group type: EXPERIMENTAL
Intervention: Escitalopram (5, 10, 15, or 20 mg/d)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 300
Study: 26731792

Group type: EXPERIMENTAL
Intervention: Riboflavin (200 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beetroot (880 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 25750137

Group type: COMPARATOR
Intervention: No drainage (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Drainage (Group B)
Number of subjects: 96
Study: 23870427

Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 100
Study: 20889235

Group type: EXPERIMENTAL
Intervention: 20% to 30% salicylic acid peels every 2 weeks for a total of 4 peels along with 4% hydroquinone cream to both sides of the face twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4% hydroquinone cream to both sides of the face twice daily
Number of subjects: 20
Study: 18431244

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sirolimus
Number of subjects: 57
Study: 15987917

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a monotherapy
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus lamivudine
Number of subjects: 814

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 814
Study: 12814993

Group type: EXPERIMENTAL
Intervention: High urinary phytoestrogen excretion
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: High urinary isoflavonoids excretion
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Increasing excretion rate of mammalian lignans
Number of subjects: 117
Study: 10585039

Group type: EXPERIMENTAL
Intervention: Milrinone treatment (0.5 microg x kg(‐1) x min(‐1) for 24 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no milrinone treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Milrinone treatment
Number of subjects: 24
Study: 8708685

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (mean dose 133.2 units Dysport)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 31
Study: 1708046

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg twice a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6753091

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (Bdp)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study: 30370831

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (walking workstation for 2.5 hours a day, 5 days/week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control phase (normal work activity)
Number of subjects: 25
Study: 28634432

Group type: EXPERIMENTAL
Intervention: Ice bag application to femoral region
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no ice bag application)
Number of subjects: 104
Study: 25890367

Group type: EXPERIMENTAL
Intervention: Adhesive enhanced closure (AEC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional wire closure (CWC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 23711618

Group type: EXPERIMENTAL
Intervention: Intramuscular IFNβ-1a (30 μg once a week)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Subcutaneous IFNβ-1b (250 μg every other day)
Number of subjects: 38
Study: 21825112

Group type: EXPERIMENTAL
Intervention: Eccentric strengthening of the hamstring muscles using the Nordic hamstring exercise
Number of subjects: 942

Group type: COMPARATOR
Intervention: Usual training program (control group)
Number of subjects: 942
Study: 19285298

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) after surgery
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (liver resection combined with PVTT removal)
Number of subjects: 126
Study: 17679585

Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Number of subjects: 0
Study: 15117710

Group type: EXPERIMENTAL
Intervention: Draw the Line/Respect the Line intervention
Number of subjects: 2829

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2829
Study: 11532838

Group type: EXPERIMENTAL
Intervention: Recurrent victimisation in year 8 (reported once or twice)
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Recurrent victimisation for girls
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Recurrent victimisation for boys
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Newly reported victimisation in year 9
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Victimisation prevalence in year 8
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of anxiety or depression prevalence in year 8
Number of subjects: 2680
Study: 9260115

Group type: EXPERIMENTAL
Intervention: Bupivicaine with fentanyl
Number of subjects: 37

Group type: COMPARATOR
Intervention: Bupivicaine alone
Number of subjects: 37
Study: 8517562

Group type: EXPERIMENTAL
Intervention: Histoacryl Blue
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 81
Study: 2952478

Group type: EXPERIMENTAL
Intervention: Topical metronidazole gel (0.75%)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 59
Study: 31648374

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol 0.5 g + ibuprofen 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol and ibuprofen (combined)
Number of subjects: 0
Study: 30725064

Group type: EXPERIMENTAL
Intervention: Virtual reality-based intervention (GWBB), 5 weeks, 2 times per week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 16
Study: 27177997

Group type: EXPERIMENTAL
Intervention: IFNB‐1b 500 µg
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: IFNB‐1b 250 µg
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: GA 20 mg QD
Number of subjects: 2244
Study: 23979360

Group type: EXPERIMENTAL
Intervention: Patients with major depression
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control group (23 women and 10 men)
Number of subjects: 30
Study: 23194185

Group type: EXPERIMENTAL
Intervention: Preschool Obesity Prevention Series (POPS)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Preschool Obesity Prevention Series (POPS) + Incredible Years Series (IYS)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual Head Start Exposure
Number of subjects: 600
Study: 20724348

Group type: EXPERIMENTAL
Intervention: Acute respiratory illness interactive template (ARI‐IT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 18448227

Group type: EXPERIMENTAL
Intervention: Dental handpiece
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Sonicare electric toothbrush
Number of subjects: 141

Group type: COMPARATOR
Intervention: Oral B 30 toothbrush
Number of subjects: 141

Group type: COMPARATOR
Intervention: Braun electric toothbrush
Number of subjects: 141
Study: 16000994

Group type: EXPERIMENTAL
Intervention: Two-sample GFR measurements using Tc-DTPA
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: One-sample GFR estimates using a new general equation
Number of subjects: 325
Study: 14523532

Group type: EXPERIMENTAL
Intervention: Oxymetazoline without preservative (Nasivin sanft 0.05% spray)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Oxymetazoline with preservative
Number of subjects: 307

Group type: COMPARATOR
Intervention: Xylometazoline with preservative
Number of subjects: 307
Study: 11789002

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin treatment in patients with baseline dyslipidaemia
Number of subjects: 0
Study: 9364291

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg, orally once daily for 3 days)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Co-amoxiclav (10 mg/kg in a 4:1 ratio, orally three times daily for 5-10 days)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 481

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 481